Skip to main content
Birte Wistinghausen, MD, Pediatric Hematology & Oncology, Washington, DC, Children's National Hospital

BirteWistinghausenMD

Pediatric Hematology & Oncology Washington, DC

Pediatric Hematologic Oncology

Oncology Medical Unit Director

Dr. Wistinghausen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Wistinghausen's full profile

Already have an account?

Education & Training

  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineFellowship, Pediatric Hematology/Oncology, 1999 - 2001
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Pediatrics, 1996 - 1999
  • University of Kiel Faculty of Medicine
    University of Kiel Faculty of MedicineClass of 1993

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1999 - 2025
  • MD State Medical License
    MD State Medical License 2018 - 2025
  • DC State Medical License
    DC State Medical License 2018 - 2024
  • PA State Medical License
    PA State Medical License 2015 - 2022
  • ME State Medical License
    ME State Medical License Active through 2003
  • American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • Top Doctors: New York Metro Area Castle Connolly, 2014
  • New York Magazine: Top Doctors Castle Connolly, 2013-2014
  • Best Doctors, Pediatric Hematology-Oncology New York Magazine, 2013-2015
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Identifying Predictive Factors for Post-Transplant Lymphoproliferative Disease (PTLD) in Pediatric Solid Organ Trasplant (SOT) Recipients with Epstein-Barr Virus (EBV)...  
    Weintraub L, Weiner C, Miloh T, Tomaino J, Joashi U, Benchimol C, Strauchen J, Wistinghausen B, J Pediatr Hematol Oncol, 1/1/2014
  • Post-transplant Lymphoproliferative Disease  
    Wistinghausen B, Gross TG, Bollard CM, Pediatric Hematology-Oncology, 1/1/2013
  • Graft rejection in pediatric liver transplant patients with EBV viremia and PTLD  
    Weiner C, Weintraub L, Wistinghausen B, Arnon R, Kerkar N, Miloh T, Pediatr Transplant, 1/1/2012
  • Join now to see all

Abstracts/Posters

  • A Lymphomatous Presentation of Mixed Lineage T/Myeloid Leukemia.
    Minkowitz S, Davis J, Petersen B, Wistinghausen B, 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Varese, Italy, 1/22/2015
  • A Case Series of Adolescent Bone Lymphoma.
    Wistinghausen B, Davis J, 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, Varese, Italy, 1/22/2015
  • Remission Induction in Mixed Lineage T/Myeloid Leukemia with Clofarabine in Patients who Fail ALL-type Therapy Followed by Hematopoietic Stem Cell Transplantation.
    Minkowitz S, Davis J, Petersen B, Wistinghausen B, International Society of Pediatric Oncology (SIOP) Meeting, Capetown, South Africa, 1/1/2015
  • Join now to see all

Lectures

  • Hematology and Oncology Disorders and Complications affecting the GI Tract: Part I 
    Icahn School of Medicine, New York, NY - 1/30/2015
  • Implications of Post-Transplant Lymphoproliferatived Disease in Pediatric Solid Organ Recipients 
    Hackensack University Hospital, Hackensack, NJ - 1/23/2015
  • Diagnosis and Treatment of Childhood and Adolescent B-Lymphoblastic Lymphoma. 
    Varese, Italy - 1/22/2015
  • Join now to see all

Press Mentions

  • Use of a Response-Adapted Ruxolitinib-Containing Regimen for the Treatment of Hemophagocytic Lymphohistiocytosis
    Use of a Response-Adapted Ruxolitinib-Containing Regimen for the Treatment of Hemophagocytic LymphohistiocytosisSeptember 16th, 2020
  • Use of a Response-Adapted Ruxolitinib-Containing Regimen for the Treatment of Hemophagocytic Lymphohistiocytosis
    Use of a Response-Adapted Ruxolitinib-Containing Regimen for the Treatment of Hemophagocytic LymphohistiocytosisJuly 27th, 2023
  • Asparaginase in ALL: Innovative Ways to Manage Toxicity
    Asparaginase in ALL: Innovative Ways to Manage ToxicityFebruary 23rd, 2024

Professional Memberships

Hospital Affiliations